On Monday, Axsome Therapeutics earned a positive adjustment to its Relative Strength (RS) Rating, from 70 to 74.
This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an RS Rating of over 80 as they launch their largest price moves. See if Axsome Therapeutics can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Axsome Therapeutics is trying to complete a cup with handle with a 97.00 entry. See if the stock can break out in volume at least 40% higher than normal.
The company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 87%. Keep an eye out for the company's next round of numbers on or around Nov. 12.
Axsome Therapeutics holds the No. 197 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and United Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
